Literature DB >> 12893670

Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination.

Joanna Moncrieff1.   

Abstract

BACKGROUND: Although there is a consensus that clozapine is more effective than conventional antipsychotic drugs for treatment-resistant schizophrenia, there is great heterogeneity among results of relevant trials. AIMS: To re-evaluate the evidence comparing clozapine with conventional antipsychotics and to investigate sources of heterogeneity.
METHOD: Individual studies were inspected with assessment of clinical relevance of results. Meta-regression analysis was performed to investigate sources of heterogeneity.
RESULTS: Ten trials were examined. Recent large-scale studies have not found a substantial advantage for clozapine, especially in terms of a clinically relevant effect. Meta-regression showed that shorter study duration, financial support from a drug company and higher baseline symptom score consistently predicted greater advantage of clozapine.
CONCLUSIONS: It may be inappropriate to combine studies in meta-analysis, given the degree of heterogeneity between their findings. The benefits of clozapine compared with conventional treatment may not be substantial.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893670     DOI: 10.1192/bjp.183.2.161

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

1.  Managing pathologic aggression in people with psychotic disorders.

Authors:  Dominique Bourget; Alain Labelle
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

2.  The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Wolf-Dieter Ludwig; Klaus Lieb
Journal:  Dtsch Arztebl Int       Date:  2010-04-23       Impact factor: 5.594

Review 3.  Reporting bias in medical research - a narrative review.

Authors:  Natalie McGauran; Beate Wieseler; Julia Kreis; Yvonne-Beatrice Schüler; Heike Kölsch; Thomas Kaiser
Journal:  Trials       Date:  2010-04-13       Impact factor: 2.279

Review 4.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

6.  Mental illness that is difficult to classify: a case study.

Authors:  Artemis Igoumenou; Maria G Turri; Raana Din; Harvey Gordon
Journal:  BMJ Case Rep       Date:  2009-12-14

Review 7.  A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia.

Authors:  Tim Calton; Michael Ferriter; Nick Huband; Helen Spandler
Journal:  Schizophr Bull       Date:  2007-06-14       Impact factor: 9.306

8.  Clozapine: Current perspective.

Authors:  Ram K Solanki; Paramjeet Singh; Mukesh K Swami
Journal:  Indian J Psychiatry       Date:  2007-10       Impact factor: 1.759

9.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

10.  Current perspectives in the treatment of resistant schizophrenia.

Authors:  R K Solanki; Paramjeet Singh; Deepti Munshi
Journal:  Indian J Psychiatry       Date:  2009 Oct-Dec       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.